Unveiling an exceptional zymogen: The single-chain form of tPA is a selective activator of NMDA receptor-dependent signaling and neurotoxicity

Cell Death and Differentiation

Volumn 19, Issue 12, 2012, Pages 1983-1991

  Parcq, J ^a   Bertrand, T ^a   Montagne, A ^a   Baron, A F ^a   MacRez, R ^a   Billard, J M ^b   Briens, A ^a   Hommet, Y ^a   Wu, J ^c   Yepes, M ^c   Lijnen, H R ^d   Dutar, P ^b   Angles Cano E ^a   Vivien, D ^a  

^a UNIVERSITÉ DE CAEN   (France)

^b INSERM   (France)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

long term potentiation; neurotoxicity; protease; tissue plasminogen activator; zymogen

Indexed keywords

CALCIUM; ENZYME PRECURSOR; GLUTAMIC ACID; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PLASMIN; SINGLE CHAIN TISSUE PLASMINOGEN ACTIVATOR; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BRAIN NERVE CELL; CALCIUM TRANSPORT; CORPUS STRIATUM; ENZYME ACTIVATION; EXCITOTOXICITY; FIBRINOLYSIS; HIPPOCAMPAL CA1 REGION; IN VITRO STUDY; IN VIVO STUDY; LONG TERM POTENTIATION; MOUSE; NERVE CELL PLASTICITY; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; SIGNAL TRANSDUCTION;

ANIMALS; CALCIUM; CELLS, CULTURED; HUMANS; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; N-METHYLASPARTATE; NEURONS; RECEPTORS, N-METHYL-D-ASPARTATE; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84869084183     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2012.86     Document Type: Article

References (40)

1. Angles-Cano E, Balaton A, Le Bonniec B, Genot E, Elion J, Sultan Y. Production of monoclonal antibodies to the high fibrin-affinity, tissue-type plasminogen activator of human plasma. Demonstration of its endothelial origin by immunolocalization. Blood 1985; 66: 913-920.
2. Rijken DC, Hoylaerts M, Collen D. Fibrinolytic properties of one-chain and twochain human extrinsic (tissue-type) plasminogen activator. J Biol Chem 1982; 257: 2920-2925.
3. Rajapakse S, Ogiwara K, Takano N, Moriyama A, Takahashi T. Biochemical characterization of human kallikrein 8 and its possible involvement in the degradation of extracellular matrix proteins. FEBS Lett 2005; 579: 6879-6884.
4. Thelwell C, Longstaff C. The regulation by fibrinogen and fibrin of tissue plasminogen activator kinetics and inhibition by plasminogen activator inhibitor 1. J Thromb Haemost 2007; 5: 804-811.
5. Baranes D, Lederfein D, Huang YY, Chen M, Bailey CH, Kandel ER. Tissue plasminogen activator contributes to the late phase of LTP and to synaptic growth in the hippocampal mossy fiber pathway. Neuron 1998; 21: 813-825.
6. Nicole O, Docagne F, Ali C, Margaill I, Carmeliet P, MacKenzie ET et al. The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat Med 2001; 7: 59-64.
7. Yepes M, Roussel BD, Ali C, Vivien D. Tissue-type plasminogen activator in the ischemic brain: more than a thrombolytic. Trends Neurosci 2009; 32: 48-55.
8. Pecorino LT, Darrow AL, Strickland S. In vitro analysis of the tissue plasminogen activator promoter reveals a GC box-binding activity present in murine brain but undetectable in kidney and liver. Mol Cell Biol 1991; 11: 3139-3147.
9. Siao C, Tsirka SE. Tissue plasminogen activator mediates microglial activation via its finger domain through annexin II. J Neurosci 2002; 22: 3352-3358.
10. Polavarapu R, Gongora MC, Yi H, Ranganthan S, Lawrence DA, Strickland D et al. Tissue-type plasminogen activator-mediated shedding of astrocytic low-density lipoprotein receptor-related protein increases the permeability of the neurovascular unit. Blood 2007; 109: 3270-3278.
11. Tsirka SE, Gualandris A, Amaral DG, Strickland S. Excitotoxin-induced neuronal degeneration and seizure are mediated by tissue plasminogen activator. Nature 1995; 377: 340-344.
12. Tsirka SE, Rogove AD, Strickland S. Neuronal cell death and tPA. Nature 1996; 384: 123-124.
13. Tsirka SE, Rogove AD, Bugge TH, Degen JL, Strickland S. An extracellular proteolytic cascade promotes neuronal degeneration in the mouse hippocampus. J Neurosci 1997; 17: 543-552.
14. Fredriksson L, Li H, Fieber C, Li X, Eriksson U. Tissue plasminogen activator is a potent activator of PDGF-CC. EMBO J 2004; 23: 3793-3802.
15. Lee H, Hwang I, Im H, Koh J, Kim Y. Non-proteolytic neurotrophic effects of tissue plasminogen activator on cultured mouse cerebrocortical neurons. J Neurochem 2007; 101: 1236-1247.
16. Sheehan JJ, Zhou C, Gravanis I, Rogove AD, Wu Y, Bogenhagen DF et al. Proteolytic activation of monocyte chemoattractant protein-1 by plasmin underlies excitotoxic neurodegeneration in mice. J Neurosci 2007; 27: 1738-1745.
17. Samson AL, Nevin ST, Medcalf RL. Low molecular weight contaminants in commercial preparations of plasmin and t-PA activate neurons. J Thromb Haemost 2008; 6: 2218-2220.
18. Harston GWJ, Sutherland BA, Kennedy J, Buchan AM. The contribution of L-arginine to the neurotoxicity of recombinant tissue plasminogen activator following cerebral ischemia: a review of rtPA neurotoxicity. J Cereb Blood Flow Metab 2010; 30: 1804-1816.
19. Mannaioni G, Orr AG, Hamill CE, Yuan H, Pedone KH, McCoy KL et al. Plasmin potentiates synaptic N-methyl-D-aspartate receptor function in hippocampal neurons through activation of protease-activated receptor-1. J Biol Chem 2008; 283: 20600-20611.
20. Hall SW, Humphries JE, Gonias SL. Inhibition of cell surface receptor-bound plasmin by alpha 2-antiplasmin and alpha 2-macroglobulin. J Biol Chem 1991; 266: 12329-12336.
21. Choi DW. Glutamate neurotoxicity in cortical cell culture is calcium dependent. Neurosci Lett 1985; 58: 293-297.
22. Baron A, Montagne A, Cassé F, Launay S, Maubert E, Ali C et al. NR2D-containing NMDA receptors mediate tissue plasminogen activator-promoted neuronal excitotoxicity. Cell Death Differ 2010; 17: 860-871.
23. Pang PT, Teng HK, Zaitsev E, Woo NT, Sakata K, Zhen S et al. Cleavage of proBDNF by tPA/plasmin is essential for long-term hippocampal plasticity. Science 2004; 306: 487-491.
24. Calabresi P, Napolitano M, Centonze D, Marfia GA, Gubellini P, Teule MA et al. Tissue plasminogen activator controls multiple forms of synaptic plasticity and memory. Eur J Neurosci 2000; 12: 1002-1012.
25. Huang YY, Bach ME, Lipp HP, Zhuo M, Wolfer DP, Hawkins RD et al. Mice lacking the gene encoding tissue-type plasminogen activator show a selective interference with latephase long-term potentiation in both Schaffer collateral and mossy fiber pathways. Proc Natl Acad Sci USA 1996; 93: 8699-8704.
26. Madani R, Hulo S, Toni N, Madani H, Steimer T, Muller D et al. Enhanced hippocampal long-term potentiation and learning by increased neuronal expression of tissue-type plasminogen activator in transgenic mice. EMBO J 1999; 18: 3007-3012.
27. Yepes M, Sandkvist M, Wong MK, Coleman TA, Smith E, Cohan SL et al. Neuroserpin reduces cerebral infarct volume and protects neurons from ischemia-induced apoptosis. Blood 2000; 96: 569-576.
28. Matys T, Strickland S. Tissue plasminogen activator and NMDA receptor cleavage. Nat Med 2003; 9: 371-372; (author reply 372-373).
29. Medina MG, Ledesma MD, Domínguez JE, Medina M, Zafra D, Alameda F et al. Tissue plasminogen activator mediates amyloid-induced neurotoxicity via Erk1/2 activation. EMBO J 2005; 24: 1706-1716.
30. Samson AL, Nevin ST, Croucher D, Niego B, Daniel PB, Weiss TW et al. Tissue-type plasminogen activator requires a co-receptor to enhance NMDA receptor function. J Neurochem 2008; 107: 1091-1101.
31. Pawlak R, Melchor JP, Matys T, Skrzypiec AE, Strickland S. Ethanol-withdrawal seizures are controlled by tissue plasminogen activator via modulation of NR2B-containing NMDA receptors. Proc Natl Acad Sci USA 2005; 102: 443-448.
32. Qian Z, Gilbert ME, Colicos MA, Kandel ER, Kuhl D. Tissue-plasminogen activator is induced as an immediate-early gene during seizure, kindling and long-term potentiation. Nature 1993; 361: 453-457.
33. Carroll PM, Tsirka SE, Richards WG, Frohman MA, Strickland S. The mouse tissue plasminogen activator gene 50 flanking region directs appropriate expression in development and a seizure-enhanced response in the CNS. Development 1994; 120: 3173-3183.
34. Teesalu T, Kulla A, Simisker A, Sirén V, Lawrence DA, Asser T et al. Tissue plasminogen activator and neuroserpin are widely expressed in the human central nervous system. Thromb Haemost 2004; 92: 358-368.
35. Barker-Carlson K, Lawrence DA, Schwartz BS. Acyl-enzyme complexes between tissuetype plasminogen activator and neuroserpin are short-lived in vitro. J Biol Chem 2002; 277: 46852-46857.
36. Takehara S, Onda M, Zhang J, Nishiyama M, Yang X, Mikami B et al. The 2.1-A crystal structure of native neuroserpin reveals unique structural elements that contribute to conformational instability. J Mol Biol 2009; 388: 11-20.
37. Lopez-Atalaya JP, Roussel BD, Levrat D, Parcq J, Nicole O, Hommet Y et al. Toward safer thrombolytic agents in stroke: molecular requirements for NMDA receptor-mediated neurotoxicity. J Cereb Blood Flow Metab 2008; 28: 1212-1221.
38. Stennicke HR, Deveraux QL, Humke EW, Reed JC, Dixit VM, Salvesen GS. Caspase-9 can be activated without proteolytic processing. J Biol Chem 1999; 274: 8359-8362.
39. Fleury V, Anglés-Cano E. Characterization of the binding of plasminogen to fibrin surfaces: the role of carboxy-terminal lysines. Biochemistry 1991; 30: 7630-7638.
40. Anderson WW, Collingridge GL. The LTP Program: a data acquisition program for on-line analysis of long-term potentiation and other synaptic events. J Neurosci Methods 2001; 108: 71-83.